Successful Management of Severe Bronchial Asthma Exacerbated by Anti-PD-L1 Treatment: A Report of Two Cases

Overview

Journal Respirol Case Rep

Date 2021 Nov 1

PMID 34721879

Citations 6

Authors

Toshiyuki Sumi

Yuta Nagahisa

Keigo Matsuura

Motoki Sekikawa

Yuichi Yamada

Hisashi Nakata

Hirofumi Chiba

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) have been used for various carcinomas. However, immune-related adverse events have been observed. There have been few reports of treatment with biologics for severe bronchial asthma induced by ICI; therefore, their efficacy is unknown. We report two cases of severe bronchial asthma requiring systemic steroid administration while using anti-programmed death-ligand 1 (PD-L1) antibody for advanced non-small-cell lung cancer. The anti-interleukin-5 antibody, mepolizumab, was introduced, resulting in the discontinuation of systemic prednisolone and good asthma control. These reports suggest that treatment with biologics may be effective in severe cases of poorly controlled bronchial asthma during ICI therapy.

Citing Articles

Pulmonary toxicity of immune checkpoint immunotherapy.

Ghanbar M, Suresh K J Clin Invest. 2024; 134(2).

PMID: 38226621 PMC: 10786690. DOI: 10.1172/JCI170503.

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin.

Homma T, Tanaka K, Takeda N, Okada Y, Torii S, Esaki H Case Rep Oncol. 2023; 16(1):1217-1222.

PMID: 37900848 PMC: 10601777. DOI: 10.1159/000534150.

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.

Faak F, Buni M, Falohun A, Lu H, Song J, Johnson D J Immunother Cancer. 2023; 11(6).

PMID: 37328287 PMC: 10277540. DOI: 10.1136/jitc-2023-006814.

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.

Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Shannon V J Immunother Precis Oncol. 2023; 6(2):111-116.

PMID: 37214206 PMC: 10195014. DOI: 10.36401/JIPO-22-30.

Immune checkpoint molecules in prevention and development of asthma.

Kanannejad Z, Soleimanian S, Ghahramani Z, Sepahi N, Mohkam M, Alyasin S Front Immunol. 2023; 14:1070779.

PMID: 36865540 PMC: 9972681. DOI: 10.3389/fimmu.2023.1070779.

References

Skribek M, Rounis K, Afshar S, Grundberg O, Friesland S, Tsakonas G . Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer. 2021; 145:245-254. DOI: 10.1016/j.ejca.2020.12.012. View

Maeno K, Fukuda S, Oguri T, Niimi A . Nivolumab-induced asthma in a patient with non-small-cell lung cancer. Ann Oncol. 2017; 28(11):2891. DOI: 10.1093/annonc/mdx455. View

Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L . Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017; 5(5):390-400. DOI: 10.1016/S2213-2600(17)30125-X. View

Bratke K, Fritz L, Nokodian F, Geissler K, Garbe K, Lommatzsch M . Differential regulation of PD-1 and its ligands in allergic asthma. Clin Exp Allergy. 2017; 47(11):1417-1425. DOI: 10.1111/cea.13017. View

Matsunaga K, Hirano T, Oka A, Tanaka A, Kanai K, Kikuchi T . Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations. J Allergy Clin Immunol Pract. 2015; 3(5):759-64.e1. DOI: 10.1016/j.jaip.2015.05.005. View

Kalmarzi R, Fattahi N, Kaviani Z, Ataee P, Mansouri M, Moradi G . Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients. Allergol Int. 2016; 66(2):326-331. DOI: 10.1016/j.alit.2016.08.008. View

Harada M, Naoi H, Yasuda K, Ito Y, Kagoo N, Kubota T . Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report. BMC Pulm Med. 2021; 21(1):6. PMC: 7789237. DOI: 10.1186/s12890-020-01375-5. View

Moore W, Kornmann O, Humbert M, Poirier C, Bel E, Kaneko N . Stopping continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2021; 59(1). PMC: 8733344. DOI: 10.1183/13993003.00396-2021. View

Roger A, Groh M, Lorillon G, Le Pendu C, Maillet J, Arangalage D . Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. Ann Rheum Dis. 2018; 78(8):e82. DOI: 10.1136/annrheumdis-2018-213857. View

10.

Scanvion Q, Bene J, Gautier S, Grandvuillemin A, Le Beller C, Chenaf C . Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. Oncoimmunology. 2020; 9(1):1722022. PMC: 7153834. DOI: 10.1080/2162402X.2020.1722022. View

11.

Wechsler M, Akuthota P, Jayne D, Khoury P, Klion A, Langford C . Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017; 376(20):1921-1932. PMC: 5548295. DOI: 10.1056/NEJMoa1702079. View

12.

Bernard-Tessier A, Jeanville P, Champiat S, Lazarovici J, Voisin A, Mateus C . Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer. 2017; 81:135-137. DOI: 10.1016/j.ejca.2017.05.017. View

13.

Cai J, Wang D, Zhang G, Guo X . The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. Onco Targets Ther. 2019; 12:8437-8445. PMC: 6800566. DOI: 10.2147/OTT.S221340. View

14.

Sullivan P, Ghushchyan V, Globe G, Schatz M . Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2017; 141(1):110-116.e7. DOI: 10.1016/j.jaci.2017.04.009. View

15.

Varricchi G, Galdiero M, Loffredo S, Lucarini V, Marone G, Mattei F . Eosinophils: The unsung heroes in cancer?. Oncoimmunology. 2018; 7(2):e1393134. PMC: 5749653. DOI: 10.1080/2162402X.2017.1393134. View

16.

Gupta A, Ikeda M, Geng B, Azmi J, Price R, Bradford E . Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019; 144(5):1336-1342.e7. DOI: 10.1016/j.jaci.2019.08.005. View

17.

Akbari O, Stock P, Singh A, Lombardi V, Lee W, Freeman G . PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2009; 3(1):81-91. PMC: 2845714. DOI: 10.1038/mi.2009.112. View

18.

Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View

19.

Krishnan T, Tomita Y, Roberts-Thomson R . A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy. Future Sci OA. 2020; 6(10):FSO608. PMC: 7720365. DOI: 10.2144/fsoa-2020-0070. View

20.

de La Rochefoucauld J, Noel N, Lambotte O . Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Intern Emerg Med. 2020; 15(4):587-598. DOI: 10.1007/s11739-020-02295-2. View